IL110581A0 - Insulin formulation - Google Patents

Insulin formulation

Info

Publication number
IL110581A0
IL110581A0 IL11058194A IL11058194A IL110581A0 IL 110581 A0 IL110581 A0 IL 110581A0 IL 11058194 A IL11058194 A IL 11058194A IL 11058194 A IL11058194 A IL 11058194A IL 110581 A0 IL110581 A0 IL 110581A0
Authority
IL
Israel
Prior art keywords
insulin
formulation
zinc
total
present
Prior art date
Application number
IL11058194A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL110581A0 publication Critical patent/IL110581A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL11058194A 1993-08-13 1994-08-08 Insulin formulation IL110581A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/106,106 US5534488A (en) 1993-08-13 1993-08-13 Insulin formulation

Publications (1)

Publication Number Publication Date
IL110581A0 true IL110581A0 (en) 1994-11-11

Family

ID=22309529

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11058194A IL110581A0 (en) 1993-08-13 1994-08-08 Insulin formulation

Country Status (27)

Country Link
US (1) US5534488A (xx)
EP (1) EP0646379B1 (xx)
JP (1) JPH07149660A (xx)
KR (1) KR950005324A (xx)
CN (1) CN1109364A (xx)
AT (1) ATE207761T1 (xx)
AU (1) AU674975B2 (xx)
BR (1) BR9403204A (xx)
CA (1) CA2129763A1 (xx)
CO (1) CO4230235A1 (xx)
CZ (1) CZ193794A3 (xx)
DE (1) DE69428860T2 (xx)
DK (1) DK0646379T3 (xx)
ES (1) ES2164691T3 (xx)
HU (1) HUT67853A (xx)
IL (1) IL110581A0 (xx)
NO (1) NO942959L (xx)
NZ (1) NZ264197A (xx)
PE (1) PE14495A1 (xx)
PH (1) PH30757A (xx)
PL (1) PL177002B1 (xx)
PT (1) PT646379E (xx)
RU (1) RU2135205C1 (xx)
TW (1) TW326394B (xx)
UA (1) UA27874C2 (xx)
YU (1) YU50494A (xx)
ZA (1) ZA945939B (xx)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578238A (en) * 1992-10-30 1996-11-26 Lord Corporation Magnetorheological materials utilizing surface-modified particles
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
EP1396272A1 (en) * 1997-12-23 2004-03-10 Eli Lilly & Company Insoluble Insulin Compositions for Controlling Blood Glucose
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
EP1196446A1 (en) * 1999-06-29 2002-04-17 Eli Lilly And Company Protamine-free insoluble acylated insulin compositions
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
JP2003528149A (ja) * 2000-03-24 2003-09-24 ジェネンテック・インコーポレーテッド 軟骨性疾患の治療のためのインスリンの使用
JP4303959B2 (ja) * 2000-10-06 2009-07-29 ジ アドバイザー − ディフェンス リサーチ アンド ディベラップメント オーガナイゼイション 磁気感受性流体組成物およびその調製方法
EP1344229B1 (en) * 2000-11-29 2008-03-05 The Adviser Defence Research & Development Organisation, Ministry of Defence, Government of India A magnetorheological fluid composition and a process for preparation thereof
CA2431033A1 (en) * 2001-02-09 2002-08-22 Genentech, Inc. Crystallization of igf-1
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
ES2664189T3 (es) 2002-01-09 2018-04-18 Emisphere Technologies, Inc. Polimorfos de 4-(4-cloro-2-hidroxibenzoil)aminobutanoato de sodio
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
EP1711220A1 (en) * 2004-01-16 2006-10-18 Biodel, Inc. Sublingual drug delivery device
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
PT1740154E (pt) * 2004-03-12 2009-09-11 Biodel Inc Composições de insulina com absorção melhorada
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
AU2005240213B8 (en) 2004-05-06 2011-10-20 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
MXPA06013251A (es) * 2004-05-14 2007-02-28 Emisphere Tech Inc Compuestos y composiciones de aril-cetona para suministrar agentes activos.
UA91512C2 (ru) 2004-07-19 2010-08-10 Биокон Лимитед Коньюгати олигомеров инсулина, их композиция (варианты) и применение
CN101014360A (zh) * 2004-08-03 2007-08-08 埃米斯菲尔技术公司 抗糖尿病口服胰岛素－双胍组合物
US20060078623A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
MX2008013165A (es) * 2006-04-12 2009-01-29 Biodel Inc Formulaciones de combinacion de insulina de accion rapida y accion larga.
PL2134351T3 (pl) 2007-03-13 2017-10-31 Jds Therapeutics Llc Sposoby i kompozycje do przedłużonego uwalniania chromu
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US9241908B2 (en) 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
CA2711561A1 (en) * 2008-01-04 2009-07-16 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
KR101820024B1 (ko) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
EP3345593B1 (de) 2009-11-13 2023-09-06 Sanofi-Aventis Deutschland GmbH Pharmazeutische zusammensetzung umfassend despro36exendin-4(1-39)-lys6-nh2 und methionin
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
WO2011103575A1 (en) * 2010-02-22 2011-08-25 Case Western Reserve University Long-acting insulin analogue preparations in soluble and crystalline forms
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
CN105749253A (zh) 2011-03-01 2016-07-13 Jds治疗有限公司 用于预防和治疗糖尿病、低血糖症及相关病症的胰岛素和铬组合物
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US11865121B2 (en) 2016-02-11 2024-01-09 Nutrition21, LLC Chromium containing compositions for improving health and fitness

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
US2882202A (en) * 1950-04-05 1959-04-14 Novo Terapeutisk Labor As Insulin crystal preparations and methods of producing them
US2882203A (en) * 1951-06-26 1959-04-14 Novo Terapeutisk Labor As Injectable insulin preparation with protracted effect
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US2819999A (en) * 1953-11-13 1958-01-14 Novo Terapeutisk Labor As Process for crystallization of insulin using freeze dried insulin as seeding material
US2799622A (en) * 1953-11-14 1957-07-16 Novo Terapeutisk Labor As Process of producing insulin crystals of substantially uniform size and compositions thereof
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus

Also Published As

Publication number Publication date
DK0646379T3 (da) 2001-12-03
PL304600A1 (en) 1995-02-20
ZA945939B (en) 1996-02-08
KR950005324A (ko) 1995-03-20
PL177002B1 (pl) 1999-09-30
RU2135205C1 (ru) 1999-08-27
ES2164691T3 (es) 2002-03-01
CN1109364A (zh) 1995-10-04
NZ264197A (en) 1997-01-29
BR9403204A (pt) 1995-04-18
CZ193794A3 (en) 1995-03-15
YU50494A (sh) 1997-01-08
DE69428860T2 (de) 2002-05-02
UA27874C2 (uk) 2000-10-16
AU7024794A (en) 1995-02-23
PH30757A (en) 1997-10-17
JPH07149660A (ja) 1995-06-13
AU674975B2 (en) 1997-01-16
EP0646379A1 (en) 1995-04-05
DE69428860D1 (de) 2001-12-06
NO942959L (no) 1995-02-14
NO942959D0 (no) 1994-08-09
HU9402287D0 (en) 1994-09-28
PT646379E (pt) 2002-03-28
PE14495A1 (es) 1995-06-02
EP0646379B1 (en) 2001-10-31
HUT67853A (en) 1995-05-29
TW326394B (en) 1998-02-11
ATE207761T1 (de) 2001-11-15
CA2129763A1 (en) 1995-02-14
CO4230235A1 (es) 1995-10-19
US5534488A (en) 1996-07-09

Similar Documents

Publication Publication Date Title
HU9402287D0 (en) Insulin formulation
AU610636B2 (en) Stabilised human protein preparations
IL72494A0 (en) Homologues of aprotinin with other aminoacids in position 15,instead of lysine,their preparation and pharmaceutical compositions containing them
WO1995013297A3 (en) Improved immunogenic compositions against human gastrin 17
DK168790D0 (xx)
CA2015186A1 (en) Nutrient composition
NZ228710A (en) Modified "echistatin" and anti-clotting pharmaceutical composition
AU2670495A (en) Ifn-beta liquid formulations
AU8188087A (en) Variants of hirudin, their use and their preparation
EP0265214A3 (en) Polypeptide preparation
AU6406590A (en) Porcine lactoferrin amino acid and cdna sequence
AU4225385A (en) After-treating nylon or natural polyamides
HU9402648D0 (en) 3,4-dioxo-1-cyclobuten-1-yl-substituted (indolyl-alkyl)-pyridine- and -pyrimidine derivatives and antimigraine composition containing them as active componens
MD1714G2 (ro) Compoziţie terapeutică în formă de sirop, conţinând N-acetilcisteină
CA2168570A1 (en) Use of growth hormone for increasement of concentration of gh, igf-i and igfbp-3 in cerebrospinal fluid
AU2557288A (en) Synergistic antifungal protein and compositions containing same
CA2153071A1 (en) Derivatized calcitonins
EP0292302A3 (en) Human splenin
HU201445B (en) Herbicide composition containing sulfonyl-urea derivative as active component and glycinamide derivative as antidotum
GB8902372D0 (en) Production of compositions containing the thyrotropin-releasing hormone(trh)or homologues thereof for uses in the regulation of the immune and related systems
TH17521A (th) สูตรผสมอินซูลิน
AU6985287A (en) 1,2,3,4-tetrahydro-6-substituted-4-aryl(or heterocyclo)-3- {(substituted amino)carbonyl}-2-thioxo(or oxo)-5-pyrimidine -carboxylic acids and esters
TH17521EX (th) สูตรผสมอินซูลิน

Legal Events

Date Code Title Description
FF Patent granted
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees